Opinion|Videos|March 28, 2025
Looking Ahead: Future Landscape for Treating OFF Time and Dyskinesia
Author(s)Daniel E. Kremens, MD, JD
An expert discusses D1 receptor agonists that reduce negative symptoms and the increasing availability of recent and upcoming PUMP options for Parkinson disease treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
SHIELD Trial Advances Combination Antiviral for Long COVID
3
Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis at AANEM 2026
4
Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis
5